STOCK TITAN

[Form 4/A] Inhibikase Therapeutics, Inc. Amended Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4/A
Rhea-AI Filing Summary

Amended Form 4 highlights — Inhibikase Therapeutics (IKT) director Vincent Aurentz filed a Form 4/A dated 07/02/2025 to correct the exercise price of a previously reported option grant.

  • Instrument: Stock option for 134,427 common shares.
  • Corrected exercise price: $2.97 per share (previous filing reported an incorrect price).
  • Grant date: 02/21/2025  |  Expiration: 02/21/2035.
  • Vesting schedule: 50% on the first anniversary and 50% on the second anniversary of the grant date, contingent on continued service.
  • Ownership form: Direct; no shares were bought or sold in the open market, so the company’s share count and public float are unchanged.

This filing is administrative in nature, rectifying a clerical error. It does not indicate any change in the director’s net exposure or signal new information about Inhibikase’s operations or financial outlook.

Punti salienti del Modulo 4 modificato — Il direttore di Inhibikase Therapeutics (IKT), Vincent Aurentz, ha presentato un Modulo 4/A datato 07/02/2025 per correggere il prezzo di esercizio di un'opzione precedentemente segnalata.

  • Strumento: Opzione su azioni per 134.427 azioni ordinarie.
  • Prezzo di esercizio corretto: 2,97 $ per azione (la segnalazione precedente riportava un prezzo errato).
  • Data di concessione: 21/02/2025  |  Scadenza: 21/02/2035.
  • Programma di maturazione: 50% al primo anniversario e 50% al secondo anniversario della data di concessione, subordinato al mantenimento del servizio.
  • Forma di proprietà: Diretta; nessuna azione è stata acquistata o venduta sul mercato aperto, quindi il numero di azioni della società e il flottante pubblico rimangono invariati.

Questa comunicazione ha carattere amministrativo e corregge un errore di trascrizione. Non indica alcuna variazione nell'esposizione netta del direttore né segnala nuove informazioni sulle operazioni o sulle prospettive finanziarie di Inhibikase.

Aspectos destacados del Formulario 4 enmendado — Vincent Aurentz, director de Inhibikase Therapeutics (IKT), presentó un Formulario 4/A fechado el 07/02/2025 para corregir el precio de ejercicio de una concesión de opción previamente reportada.

  • Instrumento: Opción sobre acciones para 134,427 acciones ordinarias.
  • Precio de ejercicio corregido: 2,97 $ por acción (la presentación anterior reportó un precio incorrecto).
  • Fecha de concesión: 21/02/2025  |  Vencimiento: 21/02/2035.
  • Calendario de adquisición: 50% en el primer aniversario y 50% en el segundo aniversario de la fecha de concesión, condicionado a la continuidad del servicio.
  • Forma de propiedad: Directa; no se compraron ni vendieron acciones en el mercado abierto, por lo que el número de acciones de la empresa y el flotante público permanecen sin cambios.

Esta presentación es de carácter administrativo, corrigiendo un error clerical. No indica ningún cambio en la exposición neta del director ni señala nueva información sobre las operaciones o perspectivas financieras de Inhibikase.

수정된 Form 4 주요 내용 — Inhibikase Therapeutics(IKT) 이사 Vincent Aurentz가 2025년 7월 2일자 Form 4/A를 제출하여 이전에 보고된 옵션 부여의 행사가격을 수정했습니다.

  • 수단: 134,427주 보통주에 대한 스톡 옵션.
  • 수정된 행사가격: 주당 2.97달러 (이전 제출서에는 잘못된 가격이 보고됨).
  • 부여일: 2025년 2월 21일  |  만료일: 2035년 2월 21일.
  • 베스팅 일정: 부여일 기준 첫 번째 기념일에 50%, 두 번째 기념일에 50%, 계속 근무 조건 하에.
  • 소유 형태: 직접 소유; 공개 시장에서 주식을 매수하거나 매도하지 않아 회사의 주식 수와 공개 유통 주식 수는 변동 없음.

이 제출은 행정적인 성격으로, 사무상의 오류를 바로잡기 위한 것입니다. 이사는 순노출에 변동이 없으며 Inhibikase의 운영이나 재무 전망에 관한 새로운 정보를 의미하지 않습니다.

Points clés du formulaire 4 modifié — Vincent Aurentz, directeur d'Inhibikase Therapeutics (IKT), a déposé un formulaire 4/A daté du 07/02/2025 pour corriger le prix d'exercice d'une attribution d'option précédemment signalée.

  • Instrument : Option d'achat d'actions portant sur 134 427 actions ordinaires.
  • Prix d'exercice corrigé : 2,97 $ par action (le dépôt précédent indiquait un prix incorrect).
  • Date d'attribution : 21/02/2025  |  Expiration : 21/02/2035.
  • Calendrier d'acquisition : 50 % au premier anniversaire et 50 % au deuxième anniversaire de la date d'attribution, sous réserve de la poursuite du service.
  • Forme de propriété : Directe ; aucune action n'a été achetée ou vendue sur le marché ouvert, de sorte que le nombre d'actions de la société et le flottant public restent inchangés.

Ce dépôt est de nature administrative et corrige une erreur matérielle. Il n'indique aucun changement dans l'exposition nette du directeur ni ne signale de nouvelles informations concernant les opérations ou les perspectives financières d'Inhibikase.

Höhepunkte des geänderten Formulars 4 — Vincent Aurentz, Direktor von Inhibikase Therapeutics (IKT), reichte ein Formular 4/A vom 07.02.2025 ein, um den Ausübungspreis einer zuvor gemeldeten Optionszuteilung zu korrigieren.

  • Instrument: Aktienoption für 134.427 Stammaktien.
  • Korrigierter Ausübungspreis: 2,97 $ pro Aktie (bei der vorherigen Meldung wurde ein falscher Preis angegeben).
  • Zuteilungsdatum: 21.02.2025  |  Ablaufdatum: 21.02.2035.
  • Vestingplan: 50 % am ersten Jahrestag und 50 % am zweiten Jahrestag des Zuteilungsdatums, abhängig vom fortgesetzten Dienst.
  • Eigentumsform: Direkt; es wurden keine Aktien am offenen Markt gekauft oder verkauft, daher bleiben die Aktienanzahl des Unternehmens und der Streubesitz unverändert.

Diese Einreichung ist administrativer Natur und korrigiert einen Schreibfehler. Sie bedeutet keine Änderung der Nettoexponierung des Direktors und signalisiert keine neuen Informationen über die Geschäftstätigkeit oder die finanzielle Perspektive von Inhibikase.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Administrative correction; no cash outflow, dilution, or trading activity—neutral for shareholders.

The Form 4/A merely adjusts the exercise price of an existing option grant to $2.97. Because the options remain unexercised and vest over two years, the filing has no immediate balance-sheet or cash-flow impact. Share count dilution occurs only upon future exercise and at a premium to today’s sub-$3 price level. The correction underscores compliance quality but carries minimal valuation relevance.

TL;DR: Filing corrects prior error, reflects sound disclosure practice; governance impact neutral.

Promptly amending insider filings when errors surface is a governance positive, but the underlying transaction—an at-market option grant—is routine. No Rule 10b5-1 plan is invoked, and no sale or purchase occurred, limiting market-moving significance. The two-year vesting aligns director incentives with long-term performance. Overall impact on governance risk profile is negligible.

Punti salienti del Modulo 4 modificato — Il direttore di Inhibikase Therapeutics (IKT), Vincent Aurentz, ha presentato un Modulo 4/A datato 07/02/2025 per correggere il prezzo di esercizio di un'opzione precedentemente segnalata.

  • Strumento: Opzione su azioni per 134.427 azioni ordinarie.
  • Prezzo di esercizio corretto: 2,97 $ per azione (la segnalazione precedente riportava un prezzo errato).
  • Data di concessione: 21/02/2025  |  Scadenza: 21/02/2035.
  • Programma di maturazione: 50% al primo anniversario e 50% al secondo anniversario della data di concessione, subordinato al mantenimento del servizio.
  • Forma di proprietà: Diretta; nessuna azione è stata acquistata o venduta sul mercato aperto, quindi il numero di azioni della società e il flottante pubblico rimangono invariati.

Questa comunicazione ha carattere amministrativo e corregge un errore di trascrizione. Non indica alcuna variazione nell'esposizione netta del direttore né segnala nuove informazioni sulle operazioni o sulle prospettive finanziarie di Inhibikase.

Aspectos destacados del Formulario 4 enmendado — Vincent Aurentz, director de Inhibikase Therapeutics (IKT), presentó un Formulario 4/A fechado el 07/02/2025 para corregir el precio de ejercicio de una concesión de opción previamente reportada.

  • Instrumento: Opción sobre acciones para 134,427 acciones ordinarias.
  • Precio de ejercicio corregido: 2,97 $ por acción (la presentación anterior reportó un precio incorrecto).
  • Fecha de concesión: 21/02/2025  |  Vencimiento: 21/02/2035.
  • Calendario de adquisición: 50% en el primer aniversario y 50% en el segundo aniversario de la fecha de concesión, condicionado a la continuidad del servicio.
  • Forma de propiedad: Directa; no se compraron ni vendieron acciones en el mercado abierto, por lo que el número de acciones de la empresa y el flotante público permanecen sin cambios.

Esta presentación es de carácter administrativo, corrigiendo un error clerical. No indica ningún cambio en la exposición neta del director ni señala nueva información sobre las operaciones o perspectivas financieras de Inhibikase.

수정된 Form 4 주요 내용 — Inhibikase Therapeutics(IKT) 이사 Vincent Aurentz가 2025년 7월 2일자 Form 4/A를 제출하여 이전에 보고된 옵션 부여의 행사가격을 수정했습니다.

  • 수단: 134,427주 보통주에 대한 스톡 옵션.
  • 수정된 행사가격: 주당 2.97달러 (이전 제출서에는 잘못된 가격이 보고됨).
  • 부여일: 2025년 2월 21일  |  만료일: 2035년 2월 21일.
  • 베스팅 일정: 부여일 기준 첫 번째 기념일에 50%, 두 번째 기념일에 50%, 계속 근무 조건 하에.
  • 소유 형태: 직접 소유; 공개 시장에서 주식을 매수하거나 매도하지 않아 회사의 주식 수와 공개 유통 주식 수는 변동 없음.

이 제출은 행정적인 성격으로, 사무상의 오류를 바로잡기 위한 것입니다. 이사는 순노출에 변동이 없으며 Inhibikase의 운영이나 재무 전망에 관한 새로운 정보를 의미하지 않습니다.

Points clés du formulaire 4 modifié — Vincent Aurentz, directeur d'Inhibikase Therapeutics (IKT), a déposé un formulaire 4/A daté du 07/02/2025 pour corriger le prix d'exercice d'une attribution d'option précédemment signalée.

  • Instrument : Option d'achat d'actions portant sur 134 427 actions ordinaires.
  • Prix d'exercice corrigé : 2,97 $ par action (le dépôt précédent indiquait un prix incorrect).
  • Date d'attribution : 21/02/2025  |  Expiration : 21/02/2035.
  • Calendrier d'acquisition : 50 % au premier anniversaire et 50 % au deuxième anniversaire de la date d'attribution, sous réserve de la poursuite du service.
  • Forme de propriété : Directe ; aucune action n'a été achetée ou vendue sur le marché ouvert, de sorte que le nombre d'actions de la société et le flottant public restent inchangés.

Ce dépôt est de nature administrative et corrige une erreur matérielle. Il n'indique aucun changement dans l'exposition nette du directeur ni ne signale de nouvelles informations concernant les opérations ou les perspectives financières d'Inhibikase.

Höhepunkte des geänderten Formulars 4 — Vincent Aurentz, Direktor von Inhibikase Therapeutics (IKT), reichte ein Formular 4/A vom 07.02.2025 ein, um den Ausübungspreis einer zuvor gemeldeten Optionszuteilung zu korrigieren.

  • Instrument: Aktienoption für 134.427 Stammaktien.
  • Korrigierter Ausübungspreis: 2,97 $ pro Aktie (bei der vorherigen Meldung wurde ein falscher Preis angegeben).
  • Zuteilungsdatum: 21.02.2025  |  Ablaufdatum: 21.02.2035.
  • Vestingplan: 50 % am ersten Jahrestag und 50 % am zweiten Jahrestag des Zuteilungsdatums, abhängig vom fortgesetzten Dienst.
  • Eigentumsform: Direkt; es wurden keine Aktien am offenen Markt gekauft oder verkauft, daher bleiben die Aktienanzahl des Unternehmens und der Streubesitz unverändert.

Diese Einreichung ist administrativer Natur und korrigiert einen Schreibfehler. Sie bedeutet keine Änderung der Nettoexponierung des Direktors und signalisiert keine neuen Informationen über die Geschäftstätigkeit oder die finanzielle Perspektive von Inhibikase.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Aurentz Vincent

(Last) (First) (Middle)
1000 N. WEST STREET, SUITE 1200

(Street)
WILMINGTON DE 19801

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Inhibikase Therapeutics, Inc. [ IKT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
02/21/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
02/25/2025
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $2.97(1) 02/21/2025 A 134,427 (2) 02/21/2035 Common Stock 134,427 $0 134,427 D
Explanation of Responses:
1. The Reporting Person's Form 4 filed with the SEC on February 25, 2025 inadvertently reported an incorrect exercise price with respect to the stock option award originally granted on February 21, 2025. This amendment is being filed solely to correct the exercise price.
2. The options will vest and become exercisable in two substantially equal installments on the first and second anniversaries of February 21, 2025, subject to the Reporting Person's continued services through such date.
/s/ David McIntyre, attorney-in-fact 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Inhibikase Therapeutics (IKT) disclose in the latest Form 4/A?

The company corrected the exercise price for a 134,427-share stock option granted to Director Vincent Aurentz, setting it at $2.97.

How many options were affected by the correction?

134,427 options were involved; no common shares were bought or sold.

When do the corrected options vest for IKT’s director?

They vest in two equal installments on the first and second anniversaries of 02/21/2025.

Does this Form 4/A change Inhibikase’s share count or cash position?

No. The filing only amends the exercise price; the options remain unexercised, so there is no immediate dilution or cash flow effect.

What is the expiration date of the corrected option grant?

The options expire on 02/21/2035 if not exercised.
Inhibikase Therapeutics Inc

NASDAQ:IKT

IKT Rankings

IKT Latest News

IKT Latest SEC Filings

IKT Stock Data

144.97M
58.74M
12.35%
76.05%
1.89%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
ATLANTA